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Abstract
Background: The prevalence of vitamin D insufficiency and secondary hyperparathyroidism is high among morbidly obese
subjects. Further, low serum levels of 25-hydroxyvitamin D (25 [OH]D) and magnesium have been associated with increased
risk of the metabolic syndrome (MS), and recently, a possible link between PTH and MS has been reported. Although it is well
known that the synthesis and secretion of PTH is regulated by serum levels of calcium, phosphate, magnesium and 25(OH)D,
less is known about the possible clustered affiliation of these parameters with MS. We aimed to explore whether MS is
associated with abnormal serum levels of PTH, 25(OH)D and magnesium in a population of morbidly obese patients.
Methods: Fasting serum levels of 25(OH)D, PTH and magnesium were assessed in a cross-sectional cohort study of 1,017
consecutive morbidly obese patients (68% women). Multiple logistic regression analyses were used to assess the independent
effect of PTH, 25(OH)D and magnesium on the odds for MS (National Cholesterol Education Program [NCEP]) after adjustment
for confounding factors.
Results: Sixty-eight percent of the patients had MS. Patients with MS had lower mean serum magnesium (P < 0.001) and higher
mean PTH (P = 0.067) than patients without MS, whereas mean 25(OH)D did not differ significantly. Patients with PTH levels
in the second to fourth quartiles had higher odds of prevalent MS (odds ratio 1.47 [95% CI 0.92–2.35], 2.33 [95% CI 1.40–3.87]
and 2.09 [95% CI 1.23–3.56], respectively), after adjustment for 25(OH)D, magnesium, calcium, phosphate, creatinine, age,
gender, season of serum sampling, BMI, current smoking, albuminuria, CRP, insulin resistance and type 2 diabetes. Further, PTH
was significantly correlated with systolic and diastolic pressure (both P < 0.001), but not with the other components of MS. The
levels of 25(OH)D and magnesium were not associated with MS in the multivariate model.
Conclusion: The PTH level, but not the vitamin D level, is an independent predictor of MS in treatment seeking morbidly obese
Caucasian women and men. Randomized controlled clinical trials, including different therapeutic strategies to lower PTH, e.g.
calcium/vitamin D supplementation and weight reduction, are necessary to explore any cause-and-effect relationship.
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Background
The metabolic syndrome (MS) is a clustering of risk fac-
tors including abdominal obesity, insulin resistance, dys-
lipidaemia, hyperglycemia, and elevated blood pressure
[1]. MS leads to increased risk of diabetes and cardiovas-
cular disease [2]. A number of studies indicate that there
is a relationship between 25-hydroxyvitamin D (25
[OH]D), calcium, insulin resistance and MS [3-6]. How-
ever, in few of these reports the findings are adjusted for
confounding variables with putative associations to MS.
Parathyroid hormone (PTH) and magnesium are of par-
ticular interest in this context, as elevated levels of PTH
and hypomagnesemia have been reported together with
MS [7-9]. Low serum magnesium levels have also been
linked to insulin resistance [10] and increased risk of type
2 diabetes [11].
Although it is well known that the synthesis and secretion
of PTH is tightly regulated by serum levels of calcium and
phosphate, serum concentrations of vitamin D and mag-
nesium do also influence PTH levels [12,13]. However,
less is known about the possible clustered affiliation of
these parameters with MS. Postmenopausal women with
normal serum calcium and creatinine but inappropriately
high PTH, had higher serum glucose, triglycerides and
BMI, but lower HDL-cholesterol concentrations than con-
trols [14]. Increasing PTH levels seem to be associated
with MS in older men, but not in women and younger
men [8,9]. In contrast, no significant relationship
between PTH, vitamin D and MS has been shown in mor-
bidly obese subjects [15].
The objective of the present study was to explore whether
MS is associated with abnormal serum levels of PTH, vita-
min D and magnesium in a large cohort of morbidly
obese patients.
Methods
Study population, data collection and ethics
A total of 1,170 consecutive morbidly obese patients who
attended a tertiary care center between November 28,
2005 and September 16, 2008, were considered for inclu-
sion. After the exclusion of 153 subjects due to previous
bariatric surgery (n = 38), non-Caucasian ethnicity (n =
31), estimated glomerular filtration rate (eGFR)<60 ml/
min/1.73 m2 (n = 42), type 1 diabetes (n = 12), serum cal-
cium > reference range (2.53 mmol/l; n = 15), or lack of
data necessary to diagnose MS (n = 18), a total of 1,017
Caucasian morbidly obese patients were included in the
analysis.
The study was approved by the Regional Committee for
Medical Research Ethics (S-05175) and was performed in
accordance with the Declaration of Helsinki [16].
Physical examination
Weight and height were measured in patients wearing
light clothing but no shoes, and BMI was calculated (kg/
m2). Waist circumference (WC) was measured at the level
midway between the lowest rib margin and the iliac crest.
Blood pressure was measured with an appropriately sized
cuff after at least 5 minutes rest with the patient seated in
an upright position. Three measurements were made and
the average of the second and third measurement was reg-
istered and used in the analyses.
Definitions
Type 2 diabetes was diagnosed in patients who had a prior
history of type 2 diabetes or a fasting serum glucose level
≥ 7.0 mmol/l [17]. Patients with previously diagnosed
hypertension, and patients with blood pressure ≥ 130/85
mmHg [1], were categorized as having elevated blood
pressure. MS was diagnosed in patients with at least 3 of
the following characteristics [1]; Elevated WC (≥ 102 cm
in men and ≥88 cm in women), elevated fasting triglycer-
ides (≥1.7 mmol/l), elevated blood pressure (see above),
elevated fasting glucose (≥ 5.6 mmol/l) or diabetes, or
reduced HDL-cholesterol (< 1.0 mmol/l in men and <1.3
mmol/l in women). Homeostasis Model Assessment
Insulin Resistance (HOMA- IR) was calculated as ([fasting
serum glucose (mmol/l) * fasting serum insulin (pmol/
l)]/135) [18]. The eGFR was calculated with the MDRD
equation; eGFR = 30849 * serum creatinine-1.154 * age-0.203
* 0.742 (if female) [19]. Albuminuria was defined as
present if the albumin/creatinine ratio was ≥ 2.5 mg/
mmol or ≥ 3.5 mg/mmol, in men and women, respec-
tively [20].
Vitamin D sufficiency, insufficiency, and deficiency were
defined as serum 25(OH)D concentrations (nmol/L) >
75, < 50, and < 25, respectively [21]. Secondary hyperpar-
athyroidism was diagnosed in patients with a serum PTH
concentration > 6.9 pmol/L and serum calcium < 2.54
mmol/l (upper limits of reference ranges).
Laboratory analyses
Blood samples were obtained after an overnight fast by
venipuncture in vacutainer gel tubes, and serum was sep-
arated from cells within 2 hours. Analyses of serum glu-
cose, creatinine, calcium, albumin, magnesium, CRP and
blood lipids were performed using dry reagent slide tech-
nology on the Vitros 950 Analyzer until November 2006
and Vitros FS 5.1 thereafter (Ortho-Clinical Diagnostics,
New York, USA). Intact PTH was assayed using an electro-
chemiluminescence immunoassay on the Elecsys 2010
(Roche Diagnostics GmbH). The coefficients of variation
for magnesium and PTH were 2% and 6%, respectively.
Glycosylated hemoglobin was analyzed by high perform-
ance liquid chromatography (HPLC) using Tosoh HLC-
723 G7 (Tosoh Corporation, Tokyo, Japan). Serum cal-Cardiovascular Diabetology 2009, 8:7 http://www.cardiab.com/content/8/1/7
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cium was adjusted for albumin; serum calcium = (serum
calcium [measured] - 0.018 * [serum albumin - 42]). Sera
for analysis of Insulin and 25(OH)D were stored at -20°C
and analysed within 1 week of blood sampling at the Hor-
mone Laboratory, Aker University Hospital. Insulin and
25(OH)D (the sum of 25-hydroxyvitamin D2 and 25-
hydroxyvitamin D3) were analyzed in serum by radioim-
munoassay (Linco Research Inc, St. Charles, MO, and Dia-
Sorin, Stillwater, MN). The interassay coefficients of
variation for insulin and 25(OH)D were 8% and 14%,
respectively. All other analyses were performed on the day
of blood sampling at Department of Clinical Chemistry at
Vestfold Hospital Trust.
Statistical analysis
Data are given as mean (SD) or proportions unless other-
wise stated. Skewed data were ln-transformed to approxi-
mate normality before statistical analyses when needed.
Differences between groups were analyzed using one way
analysis of variance or independent samples t-test for con-
tinuous data and χ2 for categorical data. Spearman's corre-
lation analysis was used to assess bivariate correlations
between continuous variables. Multiple logistic regression
with predefined explanatory variables was used to assess
odds for MS. We fitted three separate multiple logistic
regression models for MS. First (model 1), serum PTH and
parameters known to be involved in its regulation;
25(OH)D, calcium, phosphate, magnesium and creati-
nine, were entered in a multiple logistic regression analy-
sis with MS (yes/no) as the dependent variable. Second
(model 2), other confounding factors such as age, gender,
season of blood sampling, BMI, current smoking, albu-
minuria, CRP and HOMAIR were added to model 1.
Third, (model 3), presence or absence of type 2 diabetes
was added to model 2. Finally, PTH was divided into
quartiles, and this new variable replaced PTH as a contin-
uous variable in model 3. A 5% statistical significance
level was chosen. The analyses were implemented using
SPSS 16.0 (SPSS, Chicago, IL).
Results
Characteristics according to presence or absence of MS
Clinical and biochemical characteristics of the 1,017
included patients are shown in table 1. Sixty-eight percent
of the patients had MS, 43% had MS but not type 2 diabe-
tes, and 25% had both MS and type 2 diabetes. Approxi-
mately two thirds of the patients were female. All men and
women had a WC >102 cm and >88 cm, respectively. On
Table 1: Characteristics of patients according to absence or presence of metabolic syndrome
Metabolic syndrome
Variables Total Absent Present P
n 1017 323 (32%) 694 (68%)
Women 68% 73% 65% 0.008
Age (years) 42 (12) 39 (12) 44 (12) <0.001
Type 2 diabetes 26% 1.5% 37% <0.001
Coronary heart disease 4.3% 0.9% 5.9% 0.001
Elevated blood pressure 70% 40% 83% <0.001
Current smoking 26% 27% 26% 0.735
BMI (kg/m2) 44.7 (6.2) 44.2 (6.1) 45.0 (6.2) 0.079
Waist (cm) 133 (14) 130 (15) 134 (14) <0.001
PTH, vit D and magnesium
PTH (pmol/l) 5.8 (2.3) 5.6 (2.3) 5.9 (2.4) 0.067
25(OH)D (nmol/l) 52 (22) 53 (20) 52 (23) 0.127
Magnesium (mmol/l) 0.84 (0.08) 0.86 (0.07) 0.84 (0.08) <0.001
Calcium (mmol/l) 2.35 (0.07) 2.35 (0.06) 2.36 (0.07) 0.392
Phosphate (mmol/l) 1.09 (0.17) 1.09 (0.15) 1.10 (0.17) 0.517
Creatinine (μmol/l) 65 (11) 65 (10) 66 (12) 0.889
Vitamin D supplement use 11% 11% 11% 1.000
HbA1c and insulin resistance
HbA1c 6.0 (1.3) 5.3 (0.4) 6.3 (1.4) <0.001
HOMA-IR 6.3 (6.0) 3.9 (2.3) 7.5 (6.8) <0.001
Inflammation
CRP (≥ 7 mg/l) 69% 67% 70% 0.400
Drugs
Thiazides 14% 7% 17% <0.001
Loop diuretics 9% 4% 11% <0.001
Angiotensin II Type 1 Receptor 8% 3% 10% 0.001
Blocker or ACE-inhibitor use
Albuminuria 11% 4% 14% <0.001
Data are means (SD) for continuous variables and % for categorical variablesCardiovascular Diabetology 2009, 8:7 http://www.cardiab.com/content/8/1/7
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average, patients with MS were 5 years older, and they had
a higher prevalence of coronary heart disease, diabetes
and hypertension, than patients without MS (table 1). The
proportions of patients with vitamin D insufficiency and
secondary hyperparathyroidism were high, 51% and
24%, respectively, but did not differ significantly between
groups.
The patients with MS had lower mean serum magnesium
(P < 0.001) and a tendency towards higher mean serum
PTH (P = 0.067), than those without MS. In contrast, the
levels of 25(OH)D did not differ significantly between
groups.
PTH, vitamin D, magnesium, calcium, phosphate and 
components of MS
PTH was significantly correlated with 25(OH)D (r = -
0.29), calcium (r = -0.20), phosphate (r = -0.33) and mag-
nesium (r = 0.17) (all P < 0.001). As shown in table 2,
PTH correlated significantly with systolic and diastolic
blood pressure (both P < 0.001), and the patients with
elevated blood pressure had a significantly higher mean
PTH-concentration than those with normal blood pres-
sure; 5.9 (2.4) vs. 5.5 (2.2) pmol/l (P = 0.005). Finally,
25(OH)D correlated significantly with HDL-cholesterol
and triglycerides (both P < 0.001), and magnesium corre-
lated significantly with fasting glucose and insulin resist-
ance (both P < 0.001) (table 2).
PTH, vitamin D, magnesium and odds for having MS
Increasing PTH levels were associated with significantly
higher odds for having MS in all three multiple logistic
regression models (table 3). Higher magnesium levels
were significantly associated with lower odds of MS in
model 1 and 2, but not after the final adjustment for dia-
betes (model 3). No statistically significant interaction
was observed between gender and PTH (Model 3; P =
0.104). 25(OH)D was not significantly associated with
MS in the analyses. To explore a potential non-linear rela-
tionship between MS and PTH, quartiles of PTH were
implemented in an additional analysis (model 3). This
analysis confirmed an independent effect of PTH on the
occurrence of MS, showing that patients with PTH levels
in the second to fourth quartiles had a 1.5- to 2-fold
increased odds of MS (1st quartile reference, P for trend
0.008) (figure 1). The latter findings were consistent after
the exclusion of patients using thiazides, loop diuretics,
ACE-inhibitors, angiotensin II type 1 receptor blockers,
and vitamin D supplements (data not shown).
Metabolic syndrome-presence or absence of type 2 
diabetes?
The above results indicate that PTH and magnesium
might associate differently to MS depending on the pres-
ence or absence of diabetes. We therefore arranged the
patients in three groups: patients without MS, patients
with MS but without type 2 diabetes, and patients with
both MS and type 2 diabetes (Table 4). Patients with MS
but not type 2 diabetes had significantly higher PTH con-
centrations than patients without MS, whereas patients
with both MS and type 2 diabetes had significantly lower
serum magnesium concentrations than those without MS.
Discussion
The major and novel finding of this study is that the serum
level of PTH was an independent predictor of MS in a
series of 1,017 consecutive morbidly obese women and
men. In addition, our data show that morbidly obese
patients with both MS and type 2 diabetes were character-
ized by lower serum magnesium levels as compared to
patients without MS.
Although vitamin D status, as assessed by 25(OH)D, was
inversely correlated with PTH, we did not find any signif-
icant association between serum levels of 25(OH)D and
MS.
Table 2: Correlations between PTH, 25(OH)D, magnesium and individual components of metabolic syndrome including insulin 
resistance (HOMA-IR)
Fasting Glucose
(mmol/l)
Systolic Blood Pressure
(mm Hg)
Diastolic Blood Pressure
(mm Hg)
HDL-Cholesterol
(mmol/l)
Triglycerides
(mmol/l)
HOMA-Insulin Resistance
rr r r rr
PP P P PP
PTH 0.02 0.15 0.14 0.05 -0.01 -0.06
(n = 1015) 0.477 <0.001 <0.001 0.092 0.752 0.133
25(OH)D -0.04 -0.05 -0.04 0.13 -0.12 -0.09
(n = 973) 0.189 0.139 0.239 <0.001 <0.001 0.009
Magnesium -0.18 -0.05 -0.05 0.04 -0.10 -0.14
(n = 1016) <0.001 0.135 0.111 0.223 0.001 <0.001
Spearman's rank correlation coefficient (r), P = significance (2-tailed).Cardiovascular Diabetology 2009, 8:7 http://www.cardiab.com/content/8/1/7
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PTH, vitamin D and MS
Although several lines of evidence indicate that serum
PTH may be associated with metabolic disturbances, to
our knowledge, only three recently published studies have
addressed the combined effect of serum PTH and vitamin
D on MS [8,9,15]. These reports, however, diverge in their
conclusions. Our finding of a close relationship between
MS and PTH level is in contrast with the negative results
of a previous study of severely obese subjects [15], but
extend the results from a study of older mainly non-obese
men [9] to be valid in adult Caucasian treatment seeking
morbidly obese women and men. Further, although we
found a significant inverse correlation between 25(OH)D
and PTH, we could not confirm any association between
25(OH)D and MS as shown by others [8].
Magnesium, PTH, MS and diabetes
Low serum magnesium has been shown to predict type 2
diabetes [11] and MS [7]. Our study partly supports these
observations, as increasing serum magnesium was associ-
ated with lower odds for MS (model 1 and 2). In addition,
we document that patients with both type 2 diabetes and
MS had lower magnesium levels than patients without
MS. However, after the final adjustment for diabetes
(model 3), serum magnesium was not significantly asso-
ciated with MS. The apparent paradoxically low mean
serum PTH concentration in patients with both MS and
type 2 diabetes could be partly explained by the concom-
itant low magnesium level, as low serum magnesium is
known to inhibit PTH secretion [12].
What explains the possible link between PTH and MS?
The recently published link between PTH and MS in older
men, was explained by insulin resistance, high blood pres-
sure, hyperglycemia and low HDL-cholesterol [8,9]. The
hypothesis that PTH may be involved in the pathogenesis
of hypertension is also supported by a prospective popu-
lation based cohort study [22]. We confirm a positive cor-
relation between serum PTH and blood pressure, but we
could not verify any correlations between PTH and insulin
resistance [23], blood glucose or blood lipids [8,9].
Obesity, older age, and reduced daily intakes of calcium
and vitamin D are associated with higher levels of PTH.
Accordingly, weight reduction and higher intakes of cal-
cium and vitamin D have been associated with decreases
in PTH levels [24,25]. However, whether lowering of
serum PTH translates into beneficial effects on MS or its
components remains unclear.
Strengths and limitations
The validity of our findings is strengthened by the pro-
spective collection and registration of data from a homog-
enous large population of morbidly obese individuals. In
addition, the relationship between PTH and MS was
robust after adjustment for possible confounders includ-
ing age, gender, BMI, serum calcium, phosphate, magne-
sium, vitamin D levels, insulin resistance and type 2
diabetes.
Table 3: Odds for prevalent metabolic syndrome according to levels of PTH, 25(OH)D and magnesium adjusted for confounding 
factors
Model 1 Model 2 Model 3
Explanatory variables OR (95% CI) P OR (95% CI) P OR (95% CI) P
PTH 1.69 (1.12–2.56) 0.013 2.25 (1.34–3.78) 0.002 2.62 (1.52–4.53) 0.001
25(OH)D 0.86 (0.62–1.20) 0.383 0.96 (0.65–1.44) 0.860 1.06 (0.69–1.63) 0.783
Magnesium 0.02 (0.00–0.15) <0.001 0.04 (0.00–0.47) 0.010 0.22 (0.02–2.54) 0.224
Model 1. Explanatory variables in the multiple logistic regression model were PTH (ln), 25(OH)D (ln), magnesium, calcium, phosphate, and 
creatinine.
Model 2. Explanatory variables as in model 1 plus age, gender, season, BMI, current smoking, albuminuria, CRP. and HOMA-IR.
Model 3. Explanatory variables as in model 2 plus type 2 diabetes (yes/no).
Odds ratios (95% CI) for metabolic syndrome by quartiles of  PTH (reference quartile 1 = 1) after adjustment for  25(OH)D (ln), magnesium, calcium, phosphate, creatinine,  age, gender, season, BMI, current smoking, albuminuria, CRP,  HOMA-IR and type 2 diabetes (yes/no) (Model 3) Figure 1
Odds ratios (95% CI) for metabolic syndrome by 
quartiles of PTH (reference quartile 1 = 1) after 
adjustment for 25(OH)D (ln), magnesium, calcium, 
phosphate, creatinine, age, gender, season, BMI, cur-
rent smoking, albuminuria, CRP, HOMA-IR and type 
2 diabetes (yes/no) (Model 3).Cardiovascular Diabetology 2009, 8:7 http://www.cardiab.com/content/8/1/7
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Our study also had limitations. First, the cross-sectional
design makes it difficult to establish a cause-effect rela-
tionship. Second, our results may not be valid in non-
white populations. Third, the internal validity of the study
is restricted by the biochemical analyses performed at a
routine basis, thus increasing the risk of type 2 errors.
Finally, we cannot exclude the possibility that referral of
patients to a tertiary care center might have introduced a
selection bias.
Conclusion
We found that PTH was an independent predictor of MS
in a large cohort of treatment seeking morbidly obese
Caucasian women and men. If our findings are con-
firmed, randomized intervention trials employing differ-
ent strategies to lower PTH (e.g. dietary modulation or
weight reduction), with improvements in the compo-
nents of MS as primary endpoints, should be considered.
Abbreviations
(MS): The metabolic syndrome; (25 [OH]D): 25-hydrox-
yvitamin D; (PTH): Parathyroid hormone.
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